239 related articles for article (PubMed ID: 9301443)
1. Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses.
Baxevanis CN; Tsavaris NB; Papadhimitriou SI; Zarkadis IK; Papadopoulos NG; Bastounis EA; Papamichail M
Eur J Cancer; 1997 Jul; 33(8):1202-8. PubMed ID: 9301443
[TBL] [Abstract][Full Text] [Related]
2. The effect of Edrecolomab (Mo17-1A) or fluorouracil-based chemotherapy on specific immune parameters in patients with colorectal cancer. A comparative study.
Tsavaris NB; Katsoulas HL; Kosmas C; Papalambros E; Gouveris P; Papantoniou N; Rokana S; Kosmas N; Skopeliti M; Tsitsilonis OE
Oncology; 2004; 67(5-6):403-10. PubMed ID: 15713997
[TBL] [Abstract][Full Text] [Related]
3. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
[TBL] [Abstract][Full Text] [Related]
4. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
[TBL] [Abstract][Full Text] [Related]
5. Granulocyte/macrophage-colony-stimulating-factor plus interleukin-2 plus interferon alpha in the treatment of metastatic renal cell carcinoma: a pilot study.
Westermann J; Reich G; Kopp J; Haus U; Dörken B; Pezzutto A
Cancer Immunol Immunother; 2001 Jan; 49(11):613-20. PubMed ID: 11225992
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.
O'Shaughnessy JA; Venzon DJ; Gossard M; Noone MH; Denicoff A; Tolcher A; Danforth D; Jacobson J; Keegan P; Miller L; Chow C; Goldspiel B; Cowan KH
Blood; 1995 Oct; 86(8):2913-21. PubMed ID: 7579383
[TBL] [Abstract][Full Text] [Related]
7. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
Schiller JH; Hank JA; Khorsand M; Storer B; Borchert A; Huseby-Moore K; Burns D; Wesly O; Albertini MR; Wilding G; Sondel PM
Clin Cancer Res; 1996 Feb; 2(2):319-30. PubMed ID: 9816175
[TBL] [Abstract][Full Text] [Related]
8. The induction of distinct cytokine cascades correlates with different effects of granulocyte-colony stimulating factor and granulocyte/macrophage-colony-stimulating factor on the lymphocyte compartment in the course of high-dose chemotherapy for breast cancer.
Setti M; Bignardi D; Ballestrero A; Ferrando F; Musselli C; Blanchi S; Basso M; Bosco O; Balleari E; Patrone F; Indiveri F
Cancer Immunol Immunother; 1999 Sep; 48(6):287-96. PubMed ID: 10473803
[TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
10. Ifosfamide, carboplatin, and etoposide plus granulocyte-macrophage colony-stimulating factor: a phase I study with apparent activity in non-small-cell lung cancer.
Krigel RL; Palackdharry CS; Padavic K; Haas N; Kilpatrick D; Langer C; Comis R
J Clin Oncol; 1994 Jun; 12(6):1251-8. PubMed ID: 8201386
[TBL] [Abstract][Full Text] [Related]
11. Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy.
Chi KH; Chen CH; Chan WK; Chow KC; Chen SY; Yen SH; Chao JY; Chang CY; Chen KY
J Clin Oncol; 1995 Oct; 13(10):2620-8. PubMed ID: 7595716
[TBL] [Abstract][Full Text] [Related]
12. Up-regulation by granulocyte-macrophage colony-stimulating factor (GM-CSF) of induction of lymphokine (IL-2)-activated killer (LAK) cells by human blood monocytes.
Singh SM; Sone S; Inamura N; Ogura T
Int J Cancer; 1989 Jul; 44(1):170-6. PubMed ID: 2663733
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of recombinant human granulocyte-macrophage colony-stimulating factor given in combination with fluorouracil plus calcium leucovorin in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Murphy RF; Hamilton JM; Balis F; Steinberg S; Arbuck SG; Setser A; Jordan E; Chen A
J Clin Oncol; 1994 Mar; 12(3):560-8. PubMed ID: 8120554
[TBL] [Abstract][Full Text] [Related]
14. Beneficial impact of peripheral blood progenitor cells in patients with metastatic breast cancer treated with high-dose chemotherapy plus granulocyte-macrophage colony-stimulating factor. A randomized trial.
Kritz A; Crown JP; Motzer RJ; Reich LM; Heller G; Moore MP; Hamilton N; Yao TJ; Heelan RT; Schneider JG
Cancer; 1993 Apr; 71(8):2515-21. PubMed ID: 8095854
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
16. Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi's sarcoma.
Gill PS; Bernstein-Singer M; Espina BM; Rarick M; Magy F; Montgomery T; Berry MS; Levine A
AIDS; 1992 Dec; 6(12):1477-81. PubMed ID: 1283520
[TBL] [Abstract][Full Text] [Related]
17. Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity.
Liljefors M; Nilsson B; Mellstedt H; Frödin JE
Cancer Immunol Immunother; 2008 Mar; 57(3):379-88. PubMed ID: 17676322
[TBL] [Abstract][Full Text] [Related]
18. Effect of granulocyte-macrophage colony-stimulating factor on lymphokine-activated killer cell induction.
Stewart-Akers AM; Cairns JS; Tweardy DJ; McCarthy SA
Blood; 1993 May; 81(10):2671-8. PubMed ID: 8490177
[TBL] [Abstract][Full Text] [Related]
19. Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases.
Müller H; Nakchbandi V; Chatzisavvidis I; von Voigt C
Hepatogastroenterology; 2003; 50(54):1919-26. PubMed ID: 14696433
[TBL] [Abstract][Full Text] [Related]
20. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
Jones SE; Schottstaedt MW; Duncan LA; Kirby RL; Good RH; Mennel RG; George TK; Snyder DA; Watkins DL; Denham CA; Hoyes FA; Rubin AS
J Clin Oncol; 1996 Nov; 14(11):2976-83. PubMed ID: 8918495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
